Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQQD3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,485
Award facts
- Contract value 100% obligated
- $10,484.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $10,484.64 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. The delivery order, issued on January 22, 2026, with an ultimate completion date of February 12, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award was funded by DLA and represents performance under the company's larger prime vendor contract with the federal government.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to supply pharmaceutical products to military healthcare facilities worldwide. The PPV-G GEN V contract, valued at $499,999,999 with a completion date of December 31, 2036, authorizes DLA to issue delivery orders for branded and generic prescription drugs, biologics, and medical consumables. DMS Pharmaceutical Group, registered in the System for Award Management since 2001, has demonstrated substantial federal contracting activity through numerous delivery orders issued by DLA's Medical Supply Chain division, positioning the company as a critical supplier within the Department of Defense's pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FQQD3?
SPE2DR26FQQD3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26FQQD3 worth?
The government has obligated $10,485 on SPE2DR26FQQD3.
Is contract SPE2DR26FQQD3 an order under another contract?
Yes. SPE2DR26FQQD3 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQQD3 competed?
The extent of competition for SPE2DR26FQQD3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award